3Hugle T,Schuetz P,Mueller B,et al. Serum procalcitonin for discrimina-tion between septic and non septic arthritis. Clin Exp Rheumatol, 2008 ,26:453-456.
1Povoa P. C-reactive protein: a valuable marker of sepsis[J]. Intensive Care Med, 2002,28 (3) : 235-243.
2Kallio R,Bloigu A, Surcel HM,et al. C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infection and neoplastic fever in patients with solid tumours and lymphomas[J]. Support Care Cancer, 2001,9 (2) :124-128.
4Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis[J]. Am J Respir Crit Care Med, 2001,164(3), 396-402.
5Suprin E, Camus C, Gacouin A, et al. Procalcitonin: a valuable indicator of infection in a medical ICU[J]. Intensive Care Med, 2000,26 (9) : 1232-1238.
6Brunkhorst FM,Wegsheider K, Forycki ZF,et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis and septic shock[J]. Intensive Care Med,2000,26(5):S148-S152.
7Selberg O, Hecker H, Martin M,et al. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6[J]. Crit Care Medl 2000,28(8): 2793-2798.
8Luzzani A,Polati E, Dorizzi R, et al. Comparison of procalcitonin and C-reactive protein as markers of sepsis[J]. Crit Care Med,2003,31(6):1737-1741.
9Penel N, Fournier C, Clisant S, et al. Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever [J]. Support Care Cancer, 2004,12(8) :593-598.
10Mitaka C. Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome [J]. Clin Chim Acta,2005,351(1-2) :17-29.
3Patterson CM, Loebinger MR. Community acquired pneumonia:assessment and treatment [ J]. Clin Med,2012,12(3) :283-286.
4Torres A,Ramirez P,Montull B,et al. Biomarkers and community-acquired pneumonia : tailoring management with biological data[J]. Semin Respir Crit Care Med,2012,33(3) :266-271.
5Albrich WC, Dusemund F, Riiegger K, et al. Enhancement ofCURB65 score with proadrenomedullin (CURB65-A) for outcomeprediction in lower respiratory tract infections : derivation of aclinical algorithm [J]. BMC Infect Dis,2011,11:112.
6Espana PP,Capelastegui A,Bilbao A,et al. Utility of twobiomarkers for directing care among patients with non-severecommunity-acquired pneumonia [ J ]. Eur J Clin Microbiol InfectDis,2012,31( 12) :3397-3405.
7Kriiger S, Frechen D. Another brick in the wall: adrenomedullinand prognosis in community-acquired pneumonia [ J]. Eur RespirJ,2012,39(5) :1060-1061.
8Di Paola R, Talero E, Galuppo M, et al. Adrenomedullin ininflammatory process associated with experimental pulmonaryfibrosis [J]. Respir Res,2011,12:41.
9Bello S, Lasierra AB, Minchol E. Prognostic power ofproadrenomedullin in community-acquired pneumonia isindependent of aetiology [J]. Eur Respir J, 2012 ,39 ( 5 ) : 1144-1155.
10Hugle T,Schuetz P,Mueller B,et al.Serum procalcitonin for discr-imination between septic arthritis[J].Clin Exp Rheumatol,2008,26(4):453-456.
